Brain delivery of peptides and proteins

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Therapeutic proteins and peptides have been identified as showing great promise for the treatment of brain cancers and neurodegenerative diseases. However, their delivery to their intended site of action from the blood is hampered by the presence of the blood-brain barrier (BBB), a vital element in the regulation of the internal environment of the brain and the spinal cord. Peptides generally do not cross the BBB because these highly polar compounds are not lipid-soluble, and because most circulating peptides do not have access to specialized, BBB receptor-mediated transport systems. Over the past three decades, research has led to a better understanding of the transport mechanisms at the BBB, and to the development of several strategies for improving the delivery of peptides/proteins to the central nervous system (CNS).
LanguageEnglish
Title of host publicationPeptide and protein delivery
EditorsChristopher van der Walle
Pages105-122
Number of pages18
Volume1
Edition1st
DOIs
StatePublished - 2011

Fingerprint

Blood-Brain Barrier
Peptides
Brain
Proteins
Brain Diseases
Brain Neoplasms
Neurodegenerative Diseases
Spinal Cord
Central Nervous System
Lipids
Research
Therapeutics

Keywords

  • therapeutic proteins
  • peptides
  • brain
  • brain cancers
  • blood-brain barrier

Cite this

Dufès, C. (2011). Brain delivery of peptides and proteins. In C. van der Walle (Ed.), Peptide and protein delivery (1st ed., Vol. 1, pp. 105-122). DOI: 10.1016/B978-0-12-384935-9.10006-9
Dufès, Christine. / Brain delivery of peptides and proteins. Peptide and protein delivery. editor / Christopher van der Walle. Vol. 1 1st. ed. 2011. pp. 105-122
@inbook{a84030e7bd834e259b17d7c30eb8b2c7,
title = "Brain delivery of peptides and proteins",
abstract = "Therapeutic proteins and peptides have been identified as showing great promise for the treatment of brain cancers and neurodegenerative diseases. However, their delivery to their intended site of action from the blood is hampered by the presence of the blood-brain barrier (BBB), a vital element in the regulation of the internal environment of the brain and the spinal cord. Peptides generally do not cross the BBB because these highly polar compounds are not lipid-soluble, and because most circulating peptides do not have access to specialized, BBB receptor-mediated transport systems. Over the past three decades, research has led to a better understanding of the transport mechanisms at the BBB, and to the development of several strategies for improving the delivery of peptides/proteins to the central nervous system (CNS).",
keywords = "therapeutic proteins , peptides, brain, brain cancers, blood-brain barrier",
author = "Christine Duf{\`e}s",
year = "2011",
doi = "10.1016/B978-0-12-384935-9.10006-9",
language = "English",
isbn = "978-0-12-384935-9",
volume = "1",
pages = "105--122",
editor = "{van der Walle}, Christopher",
booktitle = "Peptide and protein delivery",
edition = "1st",

}

Dufès, C 2011, Brain delivery of peptides and proteins. in C van der Walle (ed.), Peptide and protein delivery. 1st edn, vol. 1, pp. 105-122. DOI: 10.1016/B978-0-12-384935-9.10006-9

Brain delivery of peptides and proteins. / Dufès, Christine.

Peptide and protein delivery. ed. / Christopher van der Walle. Vol. 1 1st. ed. 2011. p. 105-122.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Brain delivery of peptides and proteins

AU - Dufès,Christine

PY - 2011

Y1 - 2011

N2 - Therapeutic proteins and peptides have been identified as showing great promise for the treatment of brain cancers and neurodegenerative diseases. However, their delivery to their intended site of action from the blood is hampered by the presence of the blood-brain barrier (BBB), a vital element in the regulation of the internal environment of the brain and the spinal cord. Peptides generally do not cross the BBB because these highly polar compounds are not lipid-soluble, and because most circulating peptides do not have access to specialized, BBB receptor-mediated transport systems. Over the past three decades, research has led to a better understanding of the transport mechanisms at the BBB, and to the development of several strategies for improving the delivery of peptides/proteins to the central nervous system (CNS).

AB - Therapeutic proteins and peptides have been identified as showing great promise for the treatment of brain cancers and neurodegenerative diseases. However, their delivery to their intended site of action from the blood is hampered by the presence of the blood-brain barrier (BBB), a vital element in the regulation of the internal environment of the brain and the spinal cord. Peptides generally do not cross the BBB because these highly polar compounds are not lipid-soluble, and because most circulating peptides do not have access to specialized, BBB receptor-mediated transport systems. Over the past three decades, research has led to a better understanding of the transport mechanisms at the BBB, and to the development of several strategies for improving the delivery of peptides/proteins to the central nervous system (CNS).

KW - therapeutic proteins

KW - peptides

KW - brain

KW - brain cancers

KW - blood-brain barrier

U2 - 10.1016/B978-0-12-384935-9.10006-9

DO - 10.1016/B978-0-12-384935-9.10006-9

M3 - Chapter

SN - 978-0-12-384935-9

VL - 1

SP - 105

EP - 122

BT - Peptide and protein delivery

ER -

Dufès C. Brain delivery of peptides and proteins. In van der Walle C, editor, Peptide and protein delivery. 1st ed. Vol. 1. 2011. p. 105-122. Available from, DOI: 10.1016/B978-0-12-384935-9.10006-9